Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma.

IF 3.9 Q2 ONCOLOGY

Blood and Lymphatic Cancer-Targets and Therapy Pub Date : 2021-07-30 eCollection Date: 2021-01-01 DOI:10.2147/BLCTT.S267569

Georgios Pongas, Bruce Cheson

引用次数: 2

Abstract

Advanced follicular lymphoma (FL) often relapses after front-line chemoimmunotherapy, and many patients will eventually require subsequent therapy. In 2021, two new therapies were granted approval by the Food and Drug Administration (FDA), including the PI3Kδ inhibitor umbralisib and the chimeric antigen receptor-T-cell therapy (CAR-T) axicabtagene ciloleucel. Herein, we present the latest advances in the management of FL, discussing the recently approved therapies in the relapsed and refractory (R/R) setting and various new therapeutic modalities that have the potential to change the treatment landscape and natural history of R/R FL.

查看原文本刊更多论文

复发/难治性滤泡性淋巴瘤治疗的最新进展。

晚期滤泡性淋巴瘤(FL)经常在一线化疗免疫治疗后复发，许多患者最终需要后续治疗。2021年，美国食品和药物管理局(FDA)批准了两种新疗法，包括PI3Kδ抑制剂umbralisib和嵌合抗原受体- t细胞疗法(CAR-T) axicabtagene ciloleucel。在此，我们介绍了FL治疗的最新进展，讨论了最近批准的复发和难治性(R/R)治疗方法，以及各种新的治疗方式，这些治疗方式有可能改变R/R FL的治疗前景和自然历史。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood and Lymphatic Cancer-Targets and Therapy ONCOLOGY-

自引率

7.10%

发文量

审稿时长

16 weeks

期刊介绍： Blood and Lymphatic Cancer: Targets and Therapy is an international, peer reviewed, open access journal focusing on blood and lymphatic cancer research, identification of therapeutic targets, and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for the cancer patient. Specific topics covered in the journal include: Epidemiology, detection and screening Cellular research and biomarkers Identification of biotargets and agents with novel mechanisms of action Optimal clinical use of existing anticancer agents, including combination therapies Radiation, surgery, bone marrow transplantation Palliative care Patient adherence, quality of life, satisfaction Health economic evaluations.